Bioxyne Ltd
ASX:BXN
Intrinsic Value
Bioxyne Ltd. engages in the research, development, market and distribution of health products. [ Read More ]
The intrinsic value of one BXN stock under the Base Case scenario is 0.006 AUD. Compared to the current market price of 0.006 AUD, Bioxyne Ltd is Fairly Valued.
Valuation Backtest
Bioxyne Ltd
Run backtest to discover the historical profit from buying and selling BXN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bioxyne Ltd
Current Assets | 4.7m |
Cash & Short-Term Investments | 1.5m |
Receivables | 1.3m |
Other Current Assets | 1.9m |
Non-Current Assets | 71.3k |
PP&E | 71.3k |
Current Liabilities | 2.1m |
Accounts Payable | 2m |
Other Current Liabilities | 78.9k |
Non-Current Liabilities | -221.7k |
Other Non-Current Liabilities | -221.7k |
Earnings Waterfall
Bioxyne Ltd
Revenue
|
8.7m
AUD
|
Cost of Revenue
|
-5.3m
AUD
|
Gross Profit
|
3.3m
AUD
|
Operating Expenses
|
-6.4m
AUD
|
Operating Income
|
-3.1m
AUD
|
Other Expenses
|
-11m
AUD
|
Net Income
|
-14.2m
AUD
|
Free Cash Flow Analysis
Bioxyne Ltd
BXN Profitability Score
Profitability Due Diligence
Bioxyne Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Bioxyne Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
BXN Solvency Score
Solvency Due Diligence
Bioxyne Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Bioxyne Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BXN Price Targets Summary
Bioxyne Ltd
Shareholder Return
BXN Price
Bioxyne Ltd
Average Annual Return | 27.69% |
Standard Deviation of Annual Returns | 90.69% |
Max Drawdown | -83% |
Market Capitalization | 11.4m AUD |
Shares Outstanding | 1 901 650 048 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bioxyne Ltd. engages in the research, development, market and distribution of health products. The company is headquartered in Sydney, New South Wales. The company went IPO on 2000-12-14. The firm is engaged in the development of, manufacture, marketing and distribution of consumer dietary supplements based on the probiotic strain of Lactobacillus Fermentum PCC. The firm operates through two segments wholesale sales and direct sales. The firm manufactures, market, supplies and distributes its probiotic strain for over the counter dietary supplement products for the food, health, pharmaceutical and agricultural businesses. The firm is focusing on developing a range of functional food and beauty products.
Contact
IPO
Employees
Officers
The intrinsic value of one BXN stock under the Base Case scenario is 0.006 AUD.
Compared to the current market price of 0.006 AUD, Bioxyne Ltd is Fairly Valued.